What is MeiraGTx?
MeiraGTx is a vertically integrated, clinical-stage gene therapy company dedicated to developing innovative treatments for a range of genetic disorders. With a robust pipeline that includes six programs currently in clinical development, alongside a broad array of preclinical and research initiatives, MeiraGTx is positioned at the forefront of therapeutic innovation. The company's comprehensive approach spans from discovery to clinical application, aiming to address unmet medical needs through cutting-edge gene therapy solutions.
How much funding has MeiraGTx raised?
MeiraGTx has raised a total of $100M across 1 funding round:
Debt
$100M
Debt (2022): $100M with participation from Perceptive Advisors
Key Investors in MeiraGTx
Perceptive Advisors
Perceptive Advisors, a New York-based investment firm established in 1999, manages approximately $7 billion in assets and specializes in funding innovative healthcare and life sciences technologies, aligning with MeiraGTx's gene therapy focus.
What's next for MeiraGTx?
The recent major strategic investment in MeiraGTx signals a pivotal moment for the company, likely enabling accelerated development of its clinical programs and expansion of its research pipeline. This capital infusion is expected to fuel further clinical trials, enhance manufacturing capabilities, and potentially support strategic partnerships or acquisitions. As a clinical-stage enterprise, this backing is crucial for navigating the complex path to regulatory approval and commercialization, positioning MeiraGTx for significant advancements in the gene therapy landscape.
See full MeiraGTx company page
